<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814186</url>
  </required_header>
  <id_info>
    <org_study_id>B3461077</org_study_id>
    <nct_id>NCT04814186</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</brief_title>
  <official_title>A Study to Characterize the Safety and Efficacy of Tafamidis Once Daily in the Treatment of Transthyretin Amyloid Cardiomyopathy in Chinese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, multi-center, single-arm study, open-label to patients with symptomatic&#xD;
      Transthyretin amyloid cardiomyopathy (ATTR-CM) who are tafamidis na√Øve. This study is to&#xD;
      obtain safety, descriptive efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) data for&#xD;
      tafamidis orally once daily.&#xD;
&#xD;
      Subject eligibility for participation in the study will receive tafamidis once daily or 12&#xD;
      months following the assessment as the screening and baseline, month 1, 3, 6, 9 and 12 visits&#xD;
      (or Early Study Discontinuation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">December 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) during the study</measure>
    <time_frame>Baseline up to 28 days after the last dose (approximately 13 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 6 Minute Walk Distance (6MWD) at Month 6 and Month 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with TTR stabilization at each collection visit</measure>
    <time_frame>Baseline, Months 1, Month 6, and Month 12</time_frame>
    <description>TTR stabilization is a Pharmacodynamic (PD) parameter, the blood samples will be analyzed using validated analytical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary scores at Month 6 and Month 12</measure>
    <time_frame>Baseline, Months 6, Month 12</time_frame>
    <description>Domain scores are transformed to a 0 to 100 range; higher scores indicate better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of tafamidis at each collection visit</measure>
    <time_frame>Baseline, Month 1, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in N Terminal prohormone B type Natriuretic Peptide (NT-pro BNP) at Month 6 and Month 12</measure>
    <time_frame>Baseline, Month 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR concentration at each collection visit</measure>
    <time_frame>Baseline, Months 1, Month 6, and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQoL 5 Dimensions visual analogue scale (EQ-5D VAS) scores at Month 6 and Month 12</measure>
    <time_frame>Baseline, Months 6, Month 12</time_frame>
    <description>the score range is from 0-100, higher scores indicate better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-Item Short Form Survey (SF-12) scores at Month 6 and Month 12</measure>
    <time_frame>Baseline, Months 6, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Change from baseline in EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) index score at Month 6 and Month 12</measure>
    <time_frame>Baseline, Months 6, Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Transthyretin Amyloid Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Chinese participants treated with Tafamidis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment group with tafamidis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafamidis</intervention_name>
    <description>61 mg, once daily, oral administration, for 12 months.</description>
    <arm_group_label>Chinese participants treated with Tafamidis</arm_group_label>
    <other_name>Vyndamax, Tafamidis free acid, PF 06291826</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has documented ATTR-CM.&#xD;
&#xD;
          2. For the reproductive criteria for male and female participants, please refer to&#xD;
             relevant protocol sections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other acute or chronic medical or psychiatric condition including recent or active&#xD;
             suicidal ideation or behavior or laboratory abnormality, in the judgment of the&#xD;
             investigator, would make the participant inappropriate for entry into this study.&#xD;
&#xD;
          2. Participants who have prior liver and/or heart transplant.&#xD;
&#xD;
          3. Participants with primary (light chain) or secondary amyloidosis.&#xD;
&#xD;
          4. Previous administration with an investigational drug within 30 days or 5 half lives&#xD;
             preceding the first dose of study intervention used in this study (whichever is&#xD;
             longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B3461077</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafamidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

